Patient P-01337

Synthetic patientNBL-101 · Day 94 · 35–44 · M · baseline S14Steering view · 3D Open companion preview

Therapy response

Improving

Tolerance

Improving

GI state

Stable

Inflammatory state

Improving

Nutritional resilience

Stable

Discontinuation risk

63%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 46 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 46 SC-12 recommended — Supportive Compound SC-12
Day 47 Patient accepted — Started SC-12 in the companion
Day 53 GI-04 recommended — GI Support Protocol GI-04
Day 53 GI symptom burden −17% vs expected — Supportive Compound SC-12
Day 54 Patient accepted — Started GI-04 in the companion
Day 59 Tolerance state changed — Unstable → Improving
Day 62 GI symptom burden −38% vs expected — GI Support Protocol GI-04
Day 63 ME-01 recommended — Monitoring Escalation ME-01
Day 64 Patient accepted — Started ME-01 in the companion
Day 67 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
Day 68 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 46.

Primary contributors, last 14 days

Toxicity-12
Inflammatory activity-7
Treatment adherence-7
Nutritional resilience+4
GI instability+3

What helped?

Supportive Compound SC-12Day 46
Result: symptom burden −17%
GI Support Protocol GI-04Day 53
Result: symptom burden −38%
Monitoring Escalation ME-01Day 63
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dietary Support Protocol NP-02

53%

probability of meaningful tolerance improvement

284 similar trajectories
68% showed improvement
median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

51.8/100

worsening · +7.0 vs previous 14 d

Toxicity

Blood

32.1/100

improving · -8.2 vs previous 14 d

Sleep quality

Wearable

45.1/100

worsening · -7.6 vs previous 14 d

Energy level

Daily log

4/10

worsening · -0.5 vs previous 14 d

Stress level

Daily log

6/10

stable · +0.1 vs previous 14 d

Steps

Wearable

7,009

worsening · -347 vs previous 14 d

Adherence

Companion

55.9 %

worsening · -11.7 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards restoration · 41 from the failing basin, 48 from restoration.

Would help

NP-02 Dietary Support Protocol
63% improved among 63 similar · onset 10 d · confidence 61%
CR-01 Clinician Review
100% improved among 8 similar · onset 5 d · confidence 61%

Would not help

Keep histamine low
GI +6 next day on high-intake days · n 23
Keep fat low
GI +5.2 next day on high-intake days · n 28
Keep spicy low
GI +5.1 next day on high-intake days · n 14

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Histamine load
+6detractor · 95%
Dietary fat load
+5.2detractor · 95%
Spicy / capsaicin
+5.1detractor · 88%
Simple carbohydrates
+4.8detractor · 95%
Alcohol
+3.7detractor · 69%
Insoluble fibre
+1.8no signal · 31%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 44
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 35/100
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓50
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 52 and rising
Autonomic recovery ↑25
- WearableResting HR 73 bpm

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.3 · butyrate capacity 35/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 47 ms
Sleep: 7.0 h
Steps: 7,244
Resting HR: 70 bpm

Daily log: GI score 52, nutritional resilience 44, adherence 56.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01804	25%	S19	AD-05	improved	61
P-01689	25%	S13	BR-03	no change	50
P-01371	32%	S06	CR-01	improved	63
P-01696	30%	S20	CR-01	improved	59
P-01708	30%	S07	CR-01	improved	59
P-01442	29%	S13	CR-01	improved	61
P-01388	27%	S17	CR-01	improved	59
P-01877	27%	S01	CR-01	improved	67
P-01430	26%	S05	CR-01	improved	54
P-01835	26%	S17	CR-01	improved	56
P-01767	26%	S14	DT-01	no change	63
P-01376	51%	S14	GI-04	improved	53